Skip to main
ITRM
ITRM logo

ITRM Stock Forecast & Price Target

ITRM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Iterum Therapeutics PLC is positioned favorably due to significant clinical improvements demonstrated by its product, Orlynvah, particularly in the quinolone-resistant patient population, where a 26% and 34% enhancement in overall response was noted at key treatment time points. The favorable safety profile of sulopenem distinguishes it in the competitive landscape of antibiotics, positioning it as a potential first choice for treating complicated urinary tract infections in at-risk populations, such as adult women. These factors contribute to the belief that Iterum's stock is undervalued, with potential for significant upside in the near term as the company continues to leverage its commercial opportunities.

Bears say

Iterum Therapeutics is facing a negative outlook primarily due to depressed forward multiples amid ongoing market volatility, which raises concerns about investor confidence. Additionally, while cash burn could fluctuate based on pre-commercial activities and potential revenue from partnerships, the uncertainty surrounding these factors adds to risk. Moreover, the increasing prevalence of antibiotic-resistant bacteria presents a significant challenge, potentially limiting the demand for effective treatment options such as Orlynvah.

ITRM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Iterum Therapeutics Plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Iterum Therapeutics Plc (ITRM) Forecast

Analysts have given ITRM a Strong Buy based on their latest research and market trends.

According to 1 analysts, ITRM has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Iterum Therapeutics Plc (ITRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.